Millennium Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,500
| Closed | -$228K | – | 6083 |
|
|
2025
Q2 | $228K | Buy |
+1,500
| New | +$200K | ﹤0.01% | 5312 |
|
|
2025
Q1 | – | Sell |
-1,600
| Closed | -$295K | – | 5943 |
|
|
2024
Q4 | $295K | Sell |
1,600
-181,900
| -99% | -$35M | ﹤0.01% | 5081 |
|
|
2024
Q3 | $36.1M | Buy |
183,500
+162,500
| +774% | +$33.8M | 0.02% | 1052 |
|
|
2024
Q2 | $4.34M | Sell |
21,000
-63,700
| -75% | -$14.4M | ﹤0.01% | 2855 |
|
|
2024
Q1 | $22.9M | Sell |
84,700
-33,100
| -28% | -$7.9M | 0.01% | 1451 |
|
|
2023
Q4 | $27.8M | Buy |
117,800
+106,200
| +916% | +$20.9M | 0.01% | 1259 |
|
|
2023
Q3 | $2.27M | Sell |
11,600
-3,300
| -22% | -$677K | ﹤0.01% | 3436 |
|
|
2023
Q2 | $3.13M | Sell |
14,900
-4,100
| -22% | -$816K | ﹤0.01% | 3099 |
|
|
2023
Q1 | $3.83M | Buy |
19,000
+14,000
| +280% | +$3.17M | ﹤0.01% | 2845 |
|
|
2022
Q4 | $1.09M | Sell |
5,000
-12,000
| -71% | -$2.62M | ﹤0.01% | 4078 |
|
|
2022
Q3 | $3.35M | Buy |
17,000
+10,000
| +143% | +$2.16M | ﹤0.01% | 3272 |
|
|
2022
Q2 | $1.5M | Buy |
7,000
+2,000
| +40% | +$489K | ﹤0.01% | 3995 |
|
|
2022
Q1 | $1.42M | Buy |
+5,000
| New | +$1.54M | ﹤0.01% | 4180 |
|
|
2021
Q4 | – | Sell |
-40,000
| Closed | -$16.5M | – | 6877 |
|
|
2021
Q3 | $16.5M | Buy |
40,000
+5,000
| +14% | +$2.08M | 0.01% | 1504 |
|
|
2021
Q2 | $12.9M | Buy |
35,000
+15,000
| +75% | +$5.01M | 0.01% | 1604 |
|
|
2021
Q1 | $5.8M | Hold |
20,000
| – | – | ﹤0.01% | 2414 |
|
|
2020
Q4 | $5M | Sell |
20,000
-9,000
| -31% | -$2.14M | ﹤0.01% | 2443 |
|
|
2020
Q3 | $6.57K | Buy |
29,000
+19,000
| +190% | +$3.94M | 0.01% | 1595 |
|
|
2020
Q2 | $1.74M | Buy |
+10,000
| New | +$1.6M | ﹤0.01% | 2629 |
|
|
2019
Q4 | – | Sell |
-20,000
| Closed | -$2.65M | – | 4269 |
|
|
2019
Q3 | $2.65M | Buy |
+20,000
| New | +$2.68M | ﹤0.01% | 2261 |
|
|
2019
Q2 | – | Sell |
-50,000
| Closed | -$7.26M | – | 4098 |
|
|
2019
Q1 | $7.26M | Buy |
50,000
+45,000
| +900% | +$5.91M | 0.01% | 1504 |
|
|
2018
Q4 | $566K | Buy |
+5,000
| New | +$626K | ﹤0.01% | 2885 |
|
|
2017
Q4 | – | Sell |
-10,000
| Closed | -$1.08M | – | 3825 |
|
|
2017
Q3 | $1.08M | Buy |
+10,000
| New | +$1.03M | ﹤0.01% | 2475 |
|
|
2014
Q1 | – | Sell |
-4,300
| Closed | -$228K | – | 3505 |
|
|
2013
Q4 | $228K | Buy |
+4,300
| New | +$216K | ﹤0.01% | 3207 |
|
Other funds holding CRL
VCM
VPM
Millennium Management's CRL Position: Q1 2026 in Review
Millennium Management increased its Charles River Laboratories (CRL) stake by 183% in Q1 2026, buying an estimated $112M and bringing the position to 934,045 shares worth $161M. The position accounts for 0.07% of the portfolio, ranked #273.
Millennium Management first reported a position in CRL in Q2 2013 and has held it in 51 quarters since. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Millennium Management held 934,045 shares of Charles River Laboratories worth $161M as of Q1 2026.
- Millennium Management bought 603,932 Charles River Laboratories shares in Q1 2026, an estimated $112M.
- Charles River Laboratories made up 0.07% of Millennium Management's portfolio in Q1 2026, its #273 holding.
- Millennium Management first reported a position in Charles River Laboratories in Q2 2013 and has held it in 51 quarters since.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.